63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
3 citations
,
August 2013 in “Journal of the American Academy of Dermatology” A new method quickly detects hair changes from EGFR inhibitors using a microscope.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
January 2017 in “The American Pharmacists Association eBooks” January 2017 in “The American Pharmacists Association eBooks” September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
1 citations
,
March 2025 in “Skin Appendage Disorders” Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
45 citations
,
October 2009 in “Dermatology” Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
The treatment was ineffective in humans.
30 citations
,
December 2009 in “The FASEB Journal” Fluphenazine and iloprost can induce hair growth.